Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Marc Moss, David T Huang...
https://pubmed.ncbi.nlm.nih.gov/31112383/Actively Recruiting
Led by Beth Israel Deaconess Medical Center · Updated on 2026-06-29
1100
Participants Needed
33
Research Sites
26 weeks
Total Duration
This research aims to compare two ventilation strategies in patients with Acute Respiratory Distress Syndrome ARDS, a serious lung condition with high mortality despite recent advances. The study evaluates whether a personalized lung-stress oriented ventilation approach can improve survival compared to standard mechanical ventilation. This is a phase III, multi-center, randomized controlled trial designed to assess outcomes such as mortality, lung injury, and hemodynamic safety. Participants will receive one of two ventilation methods the precision ventilation strategy, which adjusts ventilator settings based on driving pressure and esophageal manometry to keep lung stress within a normal range, or guided usual care, where ventilator settings follow standard best-practice guidelines with some protocol limits. The precision strategy involves careful titration of tidal volume, positive end-expiratory pressure PEEP, and oxygen levels to reduce lung injury, while the usual care arm allows clinicians to manage ventilation within established targets. During the study, participants will be monitored for 60 days to measure mortality and other outcomes such as ventilator-free days, respiratory support-free days, and incidence of barotrauma. Researchers will collect clinical data on lung injury and hemodynamic stability, including shock-free days through Day 14. The trial includes randomization, and participants will be followed closely through the course of their ventilation treatment and recovery period. The total duration of involvement varies depending on clinical course and survival.
CONDITIONS
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
V
Valerie Goodspeed, MPH
N
Nancy Ringwood, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beth Israel Deaconess Medical Center
Lead Sponsor
NYU Langone Health
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Precision ventilation (protocolized, individualized) | Guided usual care (standard practice) |
|---|---|---|
| What it is | A protocol-driven approach to mechanical ventilation where support is individualized based on each patient's lung mechanics, using titration of tidal volume to limit driving pressure, and esophageal manometry to adjust PEEP to target transpulmonary pressures of 0 cmH2O. | Standard best-practice ventilatory management guided by clinician discretion, typically targeting tidal volumes of 6-8 ml/kg ideal body weight, plateau pressures ≤30 cmH2O, and appropriate PEEP/FiO2 combinations. Esophageal manometry is only used for data collection, not clinical adjustment. |
| Primary use | Investigational approach intended to prevent ventilator-induced lung injury by tailoring mechanical ventilation parameters to individual patient measurements. | Provides supportive mechanical ventilation for ARDS using established guideline principles, aiming to optimize oxygenation and minimize harm. |
| How it is given or performed | Ventilator settings are adjusted using esophageal manometry to titrate PEEP and limit driving pressure to ≤12 cmH2O, with respiratory rate and FiO2 personalized per patient measurements. | Clinician chooses ventilation settings based on general ARDS guidelines: adjusting PEEP/FiO2 according to accepted tables, tidal volume 6-8 ml/kg, and plateau pressures ≤30 cmH2O. Esophageal manometry is not used for decisions. |
| Evidence status | Efficacy and patient outcomes for the specific protocolized precision ventilation approach are not yet established; this large trial is designed to evaluate its impact on mortality and ventilator-free days. | Standard guideline-based ARDS ventilation is supported by previous trials and is considered effective for reducing ventilator-induced lung injury and supporting patients with ARDS. |
| Important limitations | This ventilation approach requires advanced ventilatory monitoring and esophageal manometry, which may not be available or practical in all settings. Its benefit over standard care is unproven pending current trial results. | Clinician-guided usual care does not routinely use advanced measurement like esophageal manometry, which may miss potential benefits of more individualized mechanical support. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Duration of invasive ventilation episode (up to 4 days at enrollment) and clinical course
Participants receive either the precision ventilation strategy or guided usual care ventilation while on mechanical ventilation.
Duration - 60 days from randomization
Participants are monitored for outcomes including mortality, ventilator-free days, and lung injury markers for up to 60 days after randomization.
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Marc Moss, David T Huang...
https://pubmed.ncbi.nlm.nih.gov/31112383/Jeremy R Beitler, Todd Sarge, Valerie M Banner-Goodspeed...
https://pubmed.ncbi.nlm.nih.gov/30776290/Beth Israel Deaconess Medical Center
Lead Sponsor
NYU Langone Health
Collaborating Sponsor